Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.

Esther ReyJavier AmpueroFrancisca Molina-JiménezPatricia MarañónYaiza García-GarcíaRocío Múñoz-HernándezManuel Romero-GómezCarmelo García-MonzónPedro MajanoÁgueda González-Rodríguez

Published in: Clinical and translational medicine (2021)

Keyphrases

hepatitis c virus
insulin resistance
high glucose
diabetic rats
human immunodeficiency virus
metabolic syndrome
adipose tissue
type diabetes
high fat diet
polycystic ovary syndrome
skeletal muscle
drug induced
endothelial cells
oxidative stress
hepatitis c virus infection
weight loss
glycemic control